Medical

Milestone Pharmaceuticals has announced the initiation of the Phase 3 ReVeRA-301 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is expected to enroll about 150 patients who… Read more . . .

NeOnc Technologies announced that the Phase 2a NEO100-01 study of NEO100 intranasal perillyl alcohol in patients with Grade 3 and Grade 4 IDH1-mutant gliomas met its primary endpoint, achieving a 48.9% 6-month progression-free survival rate.… Read more . . .

MannKind Corporation announced that the Phase 1b INFLO-1 safety and tolerability trial of its nintedanib dry powder inhaler met its primary endpoint, demonstrating safety and tolerability. The multiple ascending dose study enrolled 27 patients with… Read more . . .

US-based biopharm Revagenix announced that it has initiated a Phase 1 trial of Rev-56, which it describes as an “inhaled, anti-pseudomonal therapy for non-cystic fibrosis bronchiectasis (NCFB).” The first part of the study will evaluate… Read more . . .

Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… Read more . . .

Turin, Italy -based Kither Biotech says that a Phase 1 clinical study of its KIT2014 inhaled PDE3/4 inhibitor successfully demonstrated that the nebulized formulation was safe and well tolerated, with very limited systemic exposure. The… Read more . . .

MannKind Corporation announced the initiation of the Phase 2 INFLO-2 trial of its MNKD-201 nintedanib DPI in patients with idiopathic pulmonary fibrosis. The 12-week INFLO-2 study is expected to enroll approximately 210 IPF patients who… Read more . . .